- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00440791
Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The Given® Diagnostic System offers an alternative approach for endoscopic visualization of the colon using capsule endoscopy, a swallowable device which contains imagers, light sources, a power source and a RF transmitter. Advantages of the Given® Diagnostic System include the elimination of the need for conscious sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . This multi-center prospective, cohort study will evaluate the performance of PCCE in visualizing the colon. Up to 394 subjects will participate in this study. All subjects to be enrolled will be appropriate candidates for standard colonoscopy based on their clinical indication.
Each subject will undergo PCCE. All generated PCCE RAPID videos will be reviewed by blinded PCCE reading physicians. All readers, experienced in PillCam SB, will have undergone standardized training and passed a qualification test specific to reading and interpreting PCCE videos. Training will be done by reading at least 5 cases to demonstrate proficiency in interpretation of PCCE. PCCE results will be compared with that of a colonoscopy procedure.
Following PCCE procedure, standard colonoscopy will be performed by a colonoscopist blinded to the results of the PCCE. The colonoscopist will be "unblinded" during the standard colonoscopy procedure at three locations on withdrawal of the colonoscope.
Primary Endpoint - Accuracy parameters (sensitivity, specificity, NPV, PPV) of PCCE compared to standard colonoscopy.
• Number, type and severity of adverse events with both PCCE and standard colonoscopy
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85259
- Mayo Clinic Arizona
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55446
- Minnesota Gastroenterology
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic Rochester
-
-
New York
-
New York, New York, Estados Unidos, 10128
- Private Medical Facility
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239-3098
- Oregon Health Sciences University
-
-
-
-
-
Haifa, Israel
- Rambam Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
Subjects must meet one the following inclusion criteria to be eligible for enrollment into this proposed study:
Subject was referred for standard colonoscopy for one of the following reasons:
Subjects over 50 years of age with one or more of the following clinical symptoms:
rectal bleeding, hematochezia, melena, positive FOBT, recent change of bowel habits
• Any subject over 18 years of age with:
- Positive findings in the colon on a GI radiographic study (e.g., CT colonography, air-contrast barium enema, abdominal/pelvic CT scan)
- Personal history of colorectal cancer (CRC) or adenomatous colonic polyps and at least 5 years since last colonoscopy or no sooner than 3 years prior to enrollment date as long as their prior colonoscopy revealed at least one of the following high risk conditions: multiple (greater than 3)adenomas, large adenoma (greater than 1 cm) , adenomas with a villous component, adenoma with high grade dysplasia.
- Suspected or known ulcerative colitis
Exclusion criteria
The presence of any of the following will exclude a subject from study enrollment:
- Subject has dysphagia
- Subject has congestive heart failure
- Subject has renal insufficiency
- Subject is known or is suspected to suffer from intestinal obstruction.
- Subject has a cardiac pacemaker or other implanted electro medical devices.
- Subject is pregnant
- Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
- Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
- Subject has any condition, which precludes compliance with study and/or device instructions.
- Age less than 18
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Perspectivas de Tempo: Prospectivo
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Douglas Rex, M.D., Indiana University Hospital
- Investigador principal: Glenn Eisen, M.D., Oregon Health and Science University
- Investigador principal: Chris Gostout, MD, Mayo Clinic
- Investigador principal: Blair Lewis, MD, Private Medical Facility
- Investigador principal: S Ketover, MD, Minnesota Gastroenterology
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- MA-54
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .